Perfil
Michelle L.
Mellion formerly worked at Vertex Pharmaceuticals, Inc., as Medical Director from 2016 to 2018, Biogen, Inc., as Associate Medical Director from 2015 to 2016, Fulcrum Therapeutics, Inc., as Executive Medical Director from 2018 to 2022, and PepGen Inc., as Chief Medical Officer from 2024 to 2025.
Dr. Mellion received her doctorate degree from Wake Forest University and undergraduate degree from Colgate University.
Antiguos cargos conocidos de Michelle Mellion.
| Empresas | Cargo | Fin |
|---|---|---|
| PEPGEN INC. | Director Técnico/Científico/I+D | 04/04/2025 |
| FULCRUM THERAPEUTICS, INC. | Corporate Officer/Principal | 01/03/2022 |
| VERTEX PHARMACEUTICALS INCORPORATED | Director Técnico/Científico/I+D | 01/08/2018 |
| BIOGEN INC. | Corporate Officer/Principal | 01/11/2016 |
Formación de Michelle Mellion.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 6 |
|---|---|
Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Wake Forest University
Wake Forest University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Colgate University
Colgate University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines for patients by transforming gene regulation in disease | Health Technology |
PepGen Inc.
PepGen Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company which develops oligonucleotide therapeutics for treatment of severe neuromuscular and neurologic diseases | Health Technology |
- Bolsa de valores
- Insiders
- Michelle Mellion
















